



Product Information

Product ID D364086

CAS No. 944842-54-0

Chemical Name

Synonym VX-509, VRT-831509, Adelitinib

Formula $C_{18}H_{19}F_3N_6O$

Formula Wt. 392.39

Melting Point


Purity $\geq 99\%$

Solubility DMSO

Store Temp -20°C

Ship Temp Ambient

Description Decernotinib is a potent and selective inhibitor of JAK3. It exhibits anti-inflammatory effects in rat models of rheumatoid arthritis, while avoiding hematopoiesis, a problem with current non-selective JAK inhibitors. Methotrexate treatment is also improved when used in combination with decernotinib.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
D364086	1 mg	\$84.40
D364086	5 mg	\$175.20
D364086	25 mg	\$499.70
D364086	100 mg	\$1005.90

References Farmer L., Ledebor M., et al. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. *J Med Chem.* 58(18):7195-216 (2015). PMID: 26230873.

Elwood F., Witter D., et al. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. *361(2):229-44* (2017). PMID:28193636.

Genovese M., van Vollenhoven R., et al. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. *Arthritis Rheumatol.* 68(1):46-55 (2016). PMID: 26473751.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.